RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence
1Department of Neuroscience and Imaging, University G. d'Annunzio, c/o Centro Sclerosi Multipla, Ospedale Clinicizzato SS Annunziata, Via dei Vestini 31, 66100 Chieti, Italy. a.lugaresi@unich.it
Expert Opinion on Drug Delivery
|December 21, 2012
Summary
New autoinjectors for multiple sclerosis (MS) treatment may improve patient adherence. RebiSmart™ offers features like an electronic log to enhance self-injection convenience and safety.
Area of Science:
- Neurology
- Medical Devices
Background:
- First-line treatments for multiple sclerosis (MS) often involve injections, leading to adherence challenges.
- Injection-related issues are significant barriers to long-term patient compliance with disease-modifying therapies.
Purpose of the Study:
- To discuss RebiSmart™, an electronic autoinjector for subcutaneous interferon β-1a administration in MS.
- To review device features and clinical trial data, contextualized with other available autoinjectors for MS.
Main Methods:
- Focus on the features of the RebiSmart™ electronic autoinjector.
- Analysis of clinical trial data pertaining to the device's efficacy and usability.
- Comparative overview of existing autoinjectors for first-line MS therapies.
Main Results:
- RebiSmart™ is the first electronic autoinjector for MS, featuring adjustable settings and an electronic dosing log.
- The electronic log facilitates physician-patient dialogue regarding treatment adherence.
- Multidose cartridges offer environmental benefits and simpler disposal.
Conclusions:
- Innovative features of RebiSmart™ may enhance patient adherence to MS treatment.
- The device addresses common barriers such as needle phobia and needle stick injuries.
- Improved convenience and adherence can lead to better clinical outcomes in MS management.